NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced that it has learned that one patient has experienced apparent significant photo-toxicity, a known side effect of tetracyclines, while participating in the 40 mg cohort of its Phase II dose-finding study of incyclinide for the treatment of acne.
From: biz.yahoo.com
CollaGenex Pharmaceuticals Provides Update on 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the ...
Posted by Ruslan Abuzant at 5:33 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment